Physician profile
Kenneth A Kaplan
NPI 1376629147
$3,359.74
in general payments reported to CMS, 2019-2025
25 companies · $870 in 2025
The $870 reported for 2025 was more than what 76% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $159 · 2021: $281 · 2022: $562 · 2023: $778 · 2024: $531 · 2025: $870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,126 · Education: $52.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,126.20 |
| Education | $52.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $884.34 | 2019-2025 | |
| Genzyme Corporation | $792.41 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $536.95 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $347.49 | 2019-2025 | Nucala, Trelegy Ellipta |
| Kaleo, INC. | $142.19 | 2023-2024 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $92.72 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.98 | 2021-2025 | Cuvitru, Eohilia |
| Lilly USA, LLC | $73.29 | 2024-2025 | Ebglyss |
| Sanofi-Aventis U.S. LLC | $52.99 | 2023 | |
| Hikma Pharmaceuticals USA | $50.50 | 2024 | Ryaltris |
| Stryker Corporation | $42.53 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $33.36 | 2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $29.19 | 2022-2023 | |
| Alk-Abello, INC | $25.09 | 2019-2022 | |
| Ambu INC. | $23.70 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acclarent, INC | $19.57 | 2022 | |
| Smith+Nephew, INC. | $17.38 | 2025 | Tula |
| Leo Pharma INC. | $15.99 | 2022 | |
| Paratek Pharmaceuticals, INC. | $15.62 | 2025 | Xhance |
| Bio Products Laboratory USA, INC. | $15.09 | 2019 | |
| Intersect Ent, INC. | $15.00 | 2020 | |
| Incyte Corporation | $14.93 | 2024 | Opzelura |
| Csl Behring | $13.29 | 2021 | |
| Genentech USA, INC. | $13.13 | 2024 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.